DermTech Management to Present at the ICR Conference 2021

Rhea-AI Summary

DermTech (NASDAQ:DMTK), a leader in precision dermatology, announced its participation in the ICR Conference 2021 on January 14, 2021, at 10:00 a.m. Eastern time. Interested parties can access a live and archived webcast of the presentation via DermTech’s Investor Relations website for 90 days post-conference. DermTech specializes in non-invasive skin genomics, aiming to enhance diagnosis and treatment procedures while reducing unnecessary surgeries. The company focuses on the early detection of skin cancers and developing customized treatments for inflammatory diseases.

DermTech, Inc. (NASDAQ:DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that DermTech management will present at the ICR Conference 2021 on Thursday, January 14, 2021 at 10:00 a.m. Eastern time.

Interested parties may access a live webcast of the presentation and, for 90 days following the ICR Conference 2021, an archived webcast of the presentation through the “Investor Relations” section of DermTech’s website at: www.DermTech.com.

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.DermTech.com.

Forward-Looking Statements:

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: DermTech’s plans to attend investor conferences, and the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10-Q filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201228005024/en/

FAQ

When will DermTech present at the ICR Conference 2021?

DermTech will present at the ICR Conference 2021 on January 14, 2021, at 10:00 a.m. Eastern time.

How can I access DermTech's presentation from the ICR Conference?

You can access DermTech's live presentation and the archived version for 90 days on their Investor Relations website.

What is DermTech's focus in precision dermatology?

DermTech focuses on non-invasive skin genomics for accurate diagnosis and treatment of skin diseases, including early detection of skin cancers.

What innovative method does DermTech use for skin sample analysis?

DermTech uses an adhesive patch for non-invasive collection of skin samples, avoiding the need for scalpel-based procedures.

What products is DermTech developing?

DermTech is developing products for early skin cancer detection and customized drug treatments for inflammatory diseases.